





Nanotechnology is increasingly using both materials and nano-objects synthesized by living beings, most of them
produced by microbial cells. Emerging technologies and highly integrative approaches (such as ‘omics and systems
biology), that have been largely proven successful for the production of proteins and secondary metabolites are
now expected to become fully adapted for the improved biological production of nanostructured materials with
tailored properties. The so far underestimated potential of microbial cell factories in nanotechnology and nanome-
dicine is expected to emerge, in the next years, in the context of novel needs envisaged in the nanoscience
universe. This should prompt a careful revisiting of the microbial cell factories as the most versatile biological
platforms to supply functional materials for nanotechnological applications.
Generally speaking, Nanotechnology refers to the fabri-
cation, manipulation and utilization of submicron
objects, particularly those between 1 and 100 nm. Physi-
cal and chemical sciences have developed tools and pro-
cedures to fabricate nanoscale entities with intriguing
applications in electronics, material sciences and medi-
cine. In the biomedical context, the relevance of Nano-
technology relies on the particular biophysical properties
of nanoscale objects and their particular interaction with
living beings such as high diffusion in organs and tis-
sues, high surface-volume ratio, efficient uptake by
mammalian cells and high biological impact in biological
interfaces through mecano-transduction signaling [1]
and a spectrum of alternative cell activities and
responses [2]. The extraordinary bio-effectiveness of
nanoparticles has in turn derived into a strong debate
about their potential toxicity, when directly exposed to
the human body or released to the environment [3],
which is still unsolved. The biological impact of these
manmade nanoscale entities and their suitability to be
functionalized for specific binding or to act as carriers
for therapeutics empowers a spectrum of specific appli-
cations in diagnosis and therapy, including imaging, bio-
sensing, regenerative medicine, drug delivery and gene
therapy. The clinically-oriented fabrication, tailoring and
application of bio-active nanoparticles conceptually sus-
tains the Nanomedicine framework.
Bionanotechnology (as well as Nanobiotechnolgy) are
rather fuzzy terms whose overlapping meanings are
under continuous refining, as their associated technolo-
gies and applications keep evolving. They are often
understood as the generation of hybrid materials (deriv-
ing from chemical and biological synthesis), or bio-
inspired materials [4]. In a different reading frame,
Bionanotechnology can be observed as “Nanotechnology
through Biotechnology” [5], that is, the bio-fabrication
of nano-objects, or bi-functional macromolecules usable
as tools to construct or manipulate nano-objects.
Because of their wide physiological diversity, small size,
genetic manipulability and controlled culturability,
microbial cells are ideal producers of a diversity of
nanostructures, materials and instruments for Nanos-
ciences, ranging from fully natural products such as
viruses, polymers and magnetosomes, to engineered pro-
teins or protein constructs such as virus-like particles
(VLPs), and peptide-displaying phages or cells and tai-
lored metal particles (Figure 1).
In summary, microbial cells are natural producers of
(or they can be easily adapted to synthesize) nano-sized
entities with relevant biomedical applications, being the
cell factories themselves promising tools for the emer-
ging technologies and biomedical applications related
with the use of nanosized entities. Microbial Call Fac-
tories, the journal, has addressed some of these relevant
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topics through primary research papers and reviews. For
instance, Chen and coauthors [6] have recently shown
how polyhydroxyalkanoate (PHA) nanosized granules
are convenient instruments for protein purification,
while other authors [7] have improved the production of
clinically relevant microbial materials suitable for nano-
particle in vitro fabrication including alginate, hyaluronic
acid (HA) and PHA [8,9].
Moreover, cell surface display technologies [10,11] as
well as the engineering of bacterial particulate materials
(such as spores) for peptide display [12] have been
represented in our article list. Furthermore, the journal
has often addressed protein quality issues [13-19], that
are highly relevant to the design and production of pro-
tein complexes and protein nanoparticles, among which
virus like particles (VLPs) [20], self-assembling silk-like
proteins [21] and bacterial inclusion bodies [22-26] have
been particularly studied.
However, the number of submissions dealing with
Nanotechnological applications or instruments deriving
from microbial cells and the spectrum of coverage of
Nanoscience-related topics are still low. Therefore, the
editorial board of Microbial Cell Factories is pleased to
encourage all the authors working in microbiology, bio-
medicine and biomaterial sciences to consider the
potential of the Cell Factory platforms and to submit
their primary research data and reviews to the journal.
As a fully settled but highly dynamic journal, Microbial
Cell Factories is committed to fully cover emerging
technologies and scientific areas of hot interest from
which microbial products are relevant, provided the bio-
logical aspects of the production (the Cell Factory
Figure 1 Biosynthetic potential of Microbial Cell Factories in Nanosciences. Bacteria and other microbes are good producers of particulate
entities with values in Nanotechnology in general and in Nanomedicine in particular. From top left, clockwise: First, cells themselves and their
infecting viruses are used for peptide display (cell surface display or phage display technologies, respectively). Among other applications
including selecting ligands for receptor mediated drug delivery, biosensing or imaging [27-31], peptide display show important promises in
molecular biomimetics, to generate molecular links between synthetic and biological components of hybrid materials [32,33]. Also, animal, plant
and bacterial viruses, being manageable at the nanoscale, are used as scaffolds for nanofabrication of electronic components [34] and as
building blocks for functionalized surfaces [35,36], apart from their more conventional application as vehicles for the delivery of nucleic acids in
gene therapy [37,38]. Interestingly, viral components as the DNA-packaging motor of phi29 bacteriophage [39] have been explored as vehicles in
drug delivery. VLPs, produced in both eukaryotic microbes and in bacteria, apart from their conventional application in vaccination show
promising potential as nano-containers for drug delivery[40]. Other protein self assembling complexes produced in bacteria such as flagella,
explored to generate nanomotors or as templates for nanofabrication [41-43], or inclusion bodies, used as soft-matter scaffolds in tissue
engineering [44-46] or as functional materials [47] are under deep exploration and further development. Magnetosomes from magnetotactic
bacterial have shown exciting potentials in drug delivery, imaging and tissue engineering [48-53], while a diversity of metal nanoparticles
produced in bacteria, whose properties can be tuned during production, are in use or under development for nano-electronics, therapy and
imaging [54-60]. Main microbial polymers including polysaccharides, polyesters and polyamides can be nanostructured upon isolation from
producing cells for uses in material sciences, while others, such as gellan, dextran, PHA and HA, are naturally produced as nanoparticulate
materials [61-65], than can be further functionalized in vivo by the genetic engineering of producing cells [66,67].
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concept) of the model particles, structures or materials
are conveniently stressed.
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